Shares of Swiss pharmaceutical company Novartis were up about 1.5% in morning trading Monday following its announcement over the weekend that its Onbrez Breezhaler was found to be more effective at treating lung disease than a standard medicine from GlaxoSmithKline.
Continue reading Novartis’s New Lung Disease Drug Trumps GSK’s Advair in Study
Novartis’s New Lung Disease Drug Trumps GSK’s Advair in Study originally appeared on DailyFinance on Mon, 20 Sep 2010 12:36:00.
Filed Under: Company News, Health Care, GlaxoSmithKline, Novartis, Stocks in the News